Please login to the form below

Not currently logged in

ABPI welcomes new NHS research guidance for integrated care systems

Included in the proposals are calls for a fixed rebate rate of 6.88% on all eligible NHS medicine sales to be paid by the industry

UK flag over London

The Association of the British Pharmaceutical Industry (ABPI) has said it welcomes NHS England’s new research guidance for integrated care systems (ICSs), which have legal duties and other requirements that relate to research.

The guidance gives ICSs advice on meeting the legal requirements under the 2022 Health and Care Act, including promoting research, facilitating the use of research evidence, and reporting on research activity to NHS England.

An overview of research governance and the contractual requirements for delivering research is also included within the guidance, as well as a recommendation that ICSs develop a research strategy that is aligned with their five-year plan and appoint an executive lead for research.

ABPI's director of research policy, Jennifer Harris, said: “This guidance is clear on what good research practice looks like and it’s great to see it out and available for the NHS to use.

“A research-active NHS delivers huge value to patients, staff and the system itself. We hope that putting this guidance into action will help ICSs realise the huge benefits that research can offer, and help make the UK once again a destination of choice for developing the medical breakthroughs people need.”

Among the new guidance is a section dedicated to reiterating the value provided by industry trials and stressing the impact that fast study set-up time frames and meeting recruitment targets have on the UK's global competitiveness.

Around 25% of the world’s top 100 prescription medicines are discovered and developed in the UK, according to NHS England.

‘[This guidance] supports ICSs to maximise the value of their duties around research for the benefit of their population’s health and care and, through coordination across ICSs, for national and international impact,’ it said.

Earlier this month, ABPI published a new set of proposals for the UK government aimed at supporting both the NHS and economy.

Included in the proposals are calls for a fixed rebate rate of 6.88% on all eligible NHS medicine sales to be paid by the industry, with the association claiming the levy would give the health service more than £1bn a year – around £300m more than the average delivered under the old scheme before 2023.

Article by
Emily Kimber

17th March 2023

From: Regulatory



Subscribe to our email news alerts


Add my company
Genesis Research

Genesis Research is an international HEOR and RWE research organization. A leader in evidence strategy, generation and communication, the company...

Latest intelligence

The speed of science and the pace of comms
Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
Improving cardiovascular disease care and awareness
Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
Virtual Patient Engagement Program: A Customer Story
Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......